Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Wagner Heidi L
 2. Date of Event Requiring Statement (Month/Day/Year)
10/01/2015		 3. Issuer Name and Ticker or Trading Symbol
ALEXION PHARMACEUTICALS INC [ALXN]
(Last)
(First)
(Middle)
C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
SVP, Global Government Affairs
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

CHESHIRE, CT 06410		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock, par value $.0001 per share 25,916
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Option to Purchase Common Stock 05/02/2011 02/02/2021 Common Stock, par value $.0001 per share 9,500 $ 42.655 D  
Option to Purchase Common Stock 05/03/2012 02/03/2022 Common Stock, par value $.0001 per share 14,000 $ 78.88 D  
Option to Purchase Common Stock 02/12/2013 11/12/2022 Common Stock, par value $.0001 per share 3,000 $ 91.98 D  
Option to Purchase Common Stock 05/06/2013 02/06/2023 Common Stock, par value $.0001 per share 18,807 $ 93.83 D  
Option to Purchase Common Stock 02/28/2015 02/28/2024 Common Stock, par value $.0001 per share 20,000 $ 176.8 D  
Option to Purchase Common Stock 02/27/2016 02/27/2025 Common Stock, par value $.0001 per share 15,000 $ 180.37 D  
Option to Purchase Common Stock 10/01/2016 10/01/2025 Common Stock, par value $.0001 per share 5,000 $ 157.82 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Wagner Heidi L
C/O ALEXION PHARMACEUTICALS, INC
352 KNOTTER DRIVE
CHESHIRE, CT 06410		       SVP, Global Government Affairs  

Signatures

/s/ Michael V. Greco, Attorney-in-fact for Heidi L. Wagner 10/08/2015
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.